Comparative Pharmacology
Head-to-head clinical analysis: ENVARSUS XR versus LUPKYNIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENVARSUS XR versus LUPKYNIS.
ENVARSUS XR vs LUPKYNIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Calcineurin inhibitor. Binds to FKBP-12, forming a complex that inhibits calcineurin phosphatase, thereby blocking T-cell activation and IL-2 transcription.
Calcineurin inhibitor immunosuppressant that binds to cyclophilin A, inhibiting calcineurin activity, which prevents dephosphorylation and activation of nuclear factor of activated T-cells (NFAT), thereby reducing cytokine production and T-cell activation.
0.2 mg/kg/day orally once daily, with the morning meal, using extended-release tablets. Dose adjustments guided by trough concentrations.
23.7 mg orally twice daily with food.
None Documented
None Documented
Terminal half-life approximately 25-30 hours in stable renal transplant patients. Longer half-life (up to 50 hours) in patients with hepatic impairment.
Terminal elimination half-life approximately 30 hours; supports once-daily dosing; steady-state reached by day 4.
Primarily fecal (94%) with minor renal excretion (2.2% as unchanged drug). Biliary excretion is a significant route.
Primarily hepatic metabolism; <1% excreted unchanged in urine; approximately 66% of total radioactivity recovered in feces (mainly metabolites) and 22% in urine (mainly metabolites).
Category C
Category C
Calcineurin Inhibitor Immunosuppressant
Calcineurin Inhibitor Immunosuppressant